Special Drug Use Surveillance of RONAPREVE for intravenous infusion set 300 and 1332 (casirivimab [genetical recombination] and imdevimab [genetical recombination])- SARS-CoV-2 infection - (Patients with risk factors for severe disease)
Latest Information Update: 08 Jan 2022
At a glance
- Drugs Casirivimab/imdevimab (Primary) ; Casirivimab/imdevimab (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 19 Nov 2021 Status changed from not yet recruiting to recruiting.
- 17 Nov 2021 Planned number of patients changed from 550 to 770.
- 13 Oct 2021 Planned End Date changed from 30 Apr 2023 to 31 May 2023.